Comparative Pharmacology
Head-to-head clinical analysis: GLYNASE versus MICRONASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYNASE versus MICRONASE.
GLYNASE vs MICRONASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, leading to membrane depolarization, calcium influx, and exocytosis of insulin.
Initial dose 2.5-5 mg orally once daily with breakfast. Titrate by 2.5-5 mg weekly. Maximum dose 20 mg daily. Divided doses twice daily may be used for doses >10 mg.
Initial dose: 2.5-5 mg orally once daily with breakfast. Maintenance: 1.25-20 mg daily in single or divided doses. Maximum: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life: 10-16 hours; clinical context: correlates with duration of glucose-lowering effect, prolonged in renal impairment.
Terminal elimination half-life: 10 hours (range 7-20); clinical context: duration of action may be prolonged in renal impairment.
Renal: approximately 50% as metabolites and unchanged drug; fecal/biliary: minor (less than 5% as unchanged drug).
Renal: approximately 50% as metabolites and unchanged drug; biliary/fecal: approximately 50% as metabolites.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic